Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Quemaduras/tratamiento farmacológico , Timosina/análogos & derivados , Infección de Heridas/tratamiento farmacológico , Animales , Biopsia , Quemaduras/microbiología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Masculino , Músculos/microbiología , Músculos/patología , Ratas , Ratas Wistar , Timosina/uso terapéutico , Factores de Tiempo , Infección de Heridas/microbiologíaRESUMEN
Repeated introduction of thymus polypeptide drug thymoptine (8 times every 24 hours, 1 microgram/kg) led to the increase in total and non-enzymatic fibrinolytic activity of blood plasma and the decrease in fibrinogen concentration. Thymoptine could lyse non-stabilized fibrin and cause depolymerization of aggregates of fibrin monomer in virto. Highest depolymerization activity was observed at thymoptine concentration of 10 micrograms/ml.
Asunto(s)
Hemostasis/efectos de los fármacos , Péptidos/farmacología , Timosina/análogos & derivados , Extractos del Timo/farmacología , Timo , Animales , Pruebas de Coagulación Sanguínea , Relación Dosis-Respuesta a Droga , Fibrinólisis/efectos de los fármacos , Técnicas In Vitro , Masculino , RatasRESUMEN
The clinico-immunological efficacy is shown of including timoptin, levamysol, sodium nucleinate in the complex treatment of patients with rheumatoid arthritis who received glucocorticosteroids. It was found that employment of immunoregulating agents allowed to correct the immunological insufficiency in patients with rheumatoid arthritis, to increase the treatment efficacy.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/inmunología , Evaluación de Medicamentos , Quimioterapia Combinada , Humanos , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/inmunologíaRESUMEN
Stimulation of fibrinolysis, decrease in content of fibrinogen and inhibitors were observed after intravenous, intramuscular or subcutaneous administrations of thymoptine preparation (complex of peptides, isolated from mammalian thymus) at doses of 0.1 microgram, 1.0 microgram/200 g of rat body mass. A more long-term effect was found after a course of treatment involving 5 subcutaneous or intramuscular injections (1.0 microgram). Single intravenous administration of thymoptine (0.1 microgram/200 g) caused a moderate thrombolytic action. Development of thrombosis, provoked by subtotal dose of thrombin, was inhibited after subcutaneous injection of the preparation.
Asunto(s)
Fibrinólisis/efectos de los fármacos , Extractos del Timo/farmacología , Animales , Pruebas de Coagulación Sanguínea , Fibrinógeno/análisis , Activadores Plasminogénicos/sangre , Ratas , Trombosis/prevención & controlRESUMEN
Thymoptin was shown to possess the ability of lysis of the nonstabilized fibrin in vitro and of increasing the nonenzymatic fibrinolytic activity of blood plasma after eight daily intramuscular injections to rats in doses of 1 and 100 micrograms/kg body weight and during incubation with purified fibrin monomer to produce its depolymerization. Thymalin possessed no nonenzymatic fibrinolytic activity in vitro and in contrast to thymoptin at a relatively high concentration (1000 and 100 micrograms/ml) enhanced fibrin-monomer polymerization.
Asunto(s)
Productos de Degradación de Fibrina-Fibrinógeno/análisis , Fibrinolíticos/uso terapéutico , Extractos del Timo/farmacología , Hormonas del Timo/farmacología , Animales , Coagulación Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Fibrinólisis/efectos de los fármacos , Masculino , Ratas , Factores de TiempoRESUMEN
Study of the immunologic reactivity of 104 patients with chronic obstructive bronchitis revealed the deficiency of cellular immunity for the most part. The use of timoptin, sodium nucleinate and their combined application raised the clinical efficacy of the treatment of patients with chronic obstructive bronchitis, significantly reduced the concentration of medium-weight molecules in blood serum, and corrected immunity disorders.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Bronquitis/tratamiento farmacológico , Ácidos Nucleicos/uso terapéutico , Hormonas del Timo/uso terapéutico , Adyuvantes Inmunológicos/administración & dosificación , Adulto , Recuento de Células Sanguíneas , Bronquitis/sangre , Enfermedad Crónica , Quimioterapia Combinada , Humanos , Linfocitos/inmunología , Persona de Mediana Edad , Ácidos Nucleicos/administración & dosificación , Factores de Riesgo , Hormonas del Timo/administración & dosificaciónRESUMEN
It has been shown that thymosin promotes the growth of exocolonies both in the allogeneic and syngeneic systems provided the donor's bone marrow cells were incubated preliminarily in thymosin solution. It is assumed that not only thymocytes but also the humoral factor of the thymus play an important role in colony formation.